Cloud-Clone pitches assay guide for choosing ELISA, CBA, Luminex and MSD

Cloud-Clone Corp. published a selection guide for life-science researchers weighing ELISA, CBA, Luminex and MSD for targeted protein quantification. The release breaks down sensitivity, multiplexing, sample needs and workflow tradeoffs, and it positions the company’s reagent kits as options for both flow-cytometry and Luminex-based testing.

Why it matters: - Protein quantification drives cytokine studies, biomarker discovery and drug-response work in life-science labs. - The wrong assay platform can affect data quality, sample consumption, turnaround time and lab workflow efficiency. - Researchers often have to choose between affordability, multiplexing, sensitivity and instrument access.

What happened: - Cloud-Clone Corp. published a technical guide comparing ELISA, cytometric bead array (CBA), Luminex xMAP and Meso Scale Discovery (MSD) for targeted protein measurement. - The guide outlines selection strategies for single-analyte validation, multi-analyte screening, low-abundance targets and discovery-scale protein profiling. - The release also presents Cloud-Clone reagent kits for both Luminex and flow-based CBA workflows.

The details: - ELISA remains a low-cost, well-established choice for single-analyte testing. - One-step ELISA formats can complete plate-based testing within one hour and reach sensitivity down to 0.13 pg/mL. - ELISA is limited to single-plex detection, so measuring 30 cytokines requires 30 wells, repeated handling and 30 calibration standards. - ELISA typically uses 50-100 μL of sample per analyte and can increase batch-to-batch variation. - CBA runs on standard flow cytometers and supports simultaneous measurement of 5-30 analytes in one tube. - CBA assays finish in 3-4 hours and require only 25-50 μL of sample input. - High-sensitivity CBA kits can reach 0.274 pg/mL. - CBA requires careful bead handling, including thorough vortexing, because bead aggregation can distort results. - Luminex uses fluorescent-coded bead sets and can profile 2-100 analytes from a single 50 μL sample. - Luminex reaches sensitivity as low as 0.01 pg/mL and offers a dynamic range of 3.5-6 orders of magnitude. - Luminex needs dedicated hardware and specialized software. - MSD uses electrochemiluminescence on carbon electrodes and delivers fg/mL-level sensitivity with a 5-6 order-of-magnitude dynamic range. - MSD is presented as especially useful for very low-abundance proteins and as resistant to matrix interference. - Discovery-oriented platforms such as Olink PEA and SomaScan are better suited for hundreds to thousands of proteins and can use as little as 1 μL of sample, but they produce relative quantitative outputs at higher cost. - Cloud-Clone says its assay validation data show 80%-120% recovery, serial-dilution R² values of at least 0.97, and intra-assay and inter-assay coefficients of variation below 10% for both Luminex and CBA products. - Cloud-Clone says its portfolio covers more than 7,000 analytes across more than 10 species. - The portfolio includes support for human, mouse, rat, guinea pig, chicken, dog, pig and cow, plus custom development for rare species. - The company says it offers more than 350 pre-validated disease-focused assay panels across areas including autoimmunity, neuroscience, cardiovascular research, bone biology and oncology. - The company says Alzheimer’s disease panels range from 4-plex to 10-plex formats optimized for cerebrospinal fluid samples. - Bone-research panels include more than 50 validated combinations covering bone formation, bone resorption and bone remodelling pathways. - Custom panels can be assembled from the analyte library, and custom orders of up to 4 analytes can be ready in 1-3 weeks. - More information is available in the company’s announcement.

Between the lines: - The release is as much a buying guide as a product pitch. - Cloud-Clone is positioning itself around cross-platform compatibility, so labs can match reagent kits to whatever hardware they already own. - The suggested workflow favors broad screening first, then confirmation with a higher-sensitivity or lower-plex assay. - That sequencing can reduce wasted sample and help labs reserve expensive assays for the final validation step.

What’s next: - Labs evaluating new panels will likely compare their available instrumentation against the assay’s plexing needs and sample constraints. - Researchers working with scarce samples may lean toward Luminex or MSD, while routine validation studies may stay with ELISA. - Cloud-Clone is likely to compete on panel breadth, custom panel turnaround and compatibility with existing lab equipment.

The bottom line: - There is no single best protein assay platform. - The best choice depends on the study’s sensitivity needs, number of targets, sample volume and available instrumentation.